Irvine, Calif.-based Eledon Pharmaceuticals has announced promising topline results from a Phase 2a study of tegoprubart, marking the first time an investigational drug has demonstrated a reduction of inflammatory biomarkers associated with progression of amyotrophic lateral sclerosis (ALS).
“We have an investigational drug acting based on what we hypothesized it would do based on the underlying biology,” said Dr. David-Alexandre Gros, CEO of Eledon. The ALS patients in the trial are “showing some clear impacts on their inflammatory signature.”
Dr. David-Alexandre Gros
Better known as Lou Gherig’s disease, ALS affects approximately 30,000 people in the U.S., who gradually lose the ability to speak, swallow, walk or breathe independently.
Roughly 5,000 new cases are diagnosed with the disease each year.
“There’s a significant unmet need in ALS,…